General
Preferred name
ulobetasol propionate
Synonyms
CGP-14458 ()
BMY-30056 ()
HALOBETASOL PROPIONATE ()
Halobetasol (propionate) ()
BMY-30056, CGP-14458,Ulobetasol propionate ()
IDP-122 ()
Ulobetasol ()
Jemdel ()
Ulobetasol propionate ()
21-chloro diflorasone ()
Bryhali ()
Lexette ()
Ultravate ()
HALOBETASOL ()
CGP-14,458 ()
P&D ID
PD012087
CAS
66852-54-8
Tags
prodrug
natural product
drug
available
Approved by
FDA
First approval
1990
Drug indication
Inflammation
Anti-Inflammatory (topical)
Drug Status
approved
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
14
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
30
Properties
(calculated by RDKit )
Molecular Weight
484.18
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
0
cLogP
4.05
TPSA
80.67
Fraction CSP3
0.72
Chiral centers
9.0
Largest ring
6.0
QED
0.48
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Metabolism
Target
PLA2
NR3C1, PLA2G1B
Phospholipase (e.g. PLA)
Member status
member
MOA
Antiinflammatory Drugs
Glucocorticoid Receptor agonist
Indication
corticosteroid-responsive dermatoses
Therapeutic Class
Antiinflammatory Agents
Source data
